FDA approves Eli Lilly's Alzheimer's drug Kisunla

Eli Lilly's (LLY) Alzheimer's treatment drug Kisunla has gained approval by the US Food and Drug Administration. Yahoo Finance Health Reporter Anjalee Khemlani expands on Kisunla's results in slowing cognitive decline.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.

Video transcript

Time to check in on some of today's top trending tickers.

Eli Lilly receiving FDA approval for its Alzheimer's drug, Kuma.

Yahoo Finance's Angelique Kamlani has been following that story and joins us now with more on That's right, good news for Eli Lily, like you mentioned finally getting that approval.

We expected it, uh, after the uh advisory committee meeting last month in which it was unanimously recommended for approval.

This is great for Alzheimer's patients now the second drug on the market for patients.

Just a reminder.

Eli.

The drug was found to have a reduced cognitive decline by 35% over 18 months.

It's a monthly infusion, so they do have to go to a clinical care centre to receive this best for those age 60 to 85 years with mild dementia.

And, uh, it is basically delivered until the the build up in the brain.

That's what it targets clears up the price tag attached to that $32,000 for the year.

That's a little bit higher than the now competitor by in a size can be, which has been on the market for 26,500 per year.

That is delivered more frequently through infusion.

So Eli Lily did mention, of course, that the prices will vary by individual, so that is just sort of a top line price, if you will.